海辰药业
(300584)
| 流通市值：16.34亿 | | | 总市值：23.88亿 |
| 流通股本：8211.51万 | | | 总股本：1.20亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 142,649,339.94 | 504,360,394.59 | 360,497,824.16 | 236,532,812.43 |
| 营业收入 | 142,649,339.94 | 504,360,394.59 | 360,497,824.16 | 236,532,812.43 |
| 二、营业总成本 | 124,158,918.05 | 454,644,738.59 | 324,027,907.82 | 205,032,329.98 |
| 营业成本 | 19,842,260.49 | 84,980,990.82 | 60,911,488.02 | 37,517,295.31 |
| 税金及附加 | 3,185,104.11 | 10,641,872.71 | 7,940,032.54 | 5,362,618.8 |
| 销售费用 | 56,390,082.47 | 201,766,882.46 | 150,433,501.51 | 95,581,574.02 |
| 管理费用 | 38,657,009.14 | 107,887,139.55 | 63,620,585.66 | 42,283,430.43 |
| 研发费用 | 4,331,960.14 | 40,275,869.51 | 34,268,297.38 | 19,738,113.2 |
| 财务费用 | 1,752,501.7 | 9,091,983.54 | 6,854,002.71 | 4,549,298.22 |
| 其中:利息费用 | 1,774,305.64 | 8,983,022.82 | 6,820,431.18 | 4,590,276.92 |
| 其中:利息收入 | 21,383.36 | 113,603.48 | 94,120.82 | 73,474.85 |
| 加:公允价值变动收益 | - | - | 1,705.87 | - |
| 加:投资收益 | -7,469.68 | 3,318.69 | -120,412.6 | -28,020.77 |
| 资产处置收益 | - | - | -52,414.95 | -25,197.5 |
| 资产减值损失(新) | -3,931,326.87 | -9,884,051.74 | -6,808,591.63 | -4,389,932.75 |
| 信用减值损失(新) | 1,437,594.09 | 834,439.48 | 1,189,426.54 | 813,949.88 |
| 其他收益 | 528,271.12 | 1,138,876.31 | 681,467.03 | 460,081.92 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 16,517,490.55 | 41,808,238.74 | 31,361,096.6 | 28,331,363.23 |
| 加:营业外收入 | 19,301.18 | 570,272.45 | 24,264.04 | 11,485.48 |
| 减:营业外支出 | 184,971.08 | 1,348,204.26 | 1,175,224.66 | 957,651.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 16,351,820.65 | 41,030,306.93 | 30,210,135.98 | 27,385,197.64 |
| 减:所得税费用 | 1,388,950.76 | 867,335.68 | 2,093,329.35 | 2,648,848.71 |
| 六、净利润 | 14,962,869.89 | 40,162,971.25 | 28,116,806.63 | 24,736,348.93 |
| 持续经营净利润 | 14,962,869.89 | 40,162,971.25 | 28,116,806.63 | 24,736,348.93 |
| 归属于母公司股东的净利润 | 15,036,959.76 | 40,217,910.88 | 28,116,806.63 | 24,736,348.93 |
| 少数股东损益 | -74,089.87 | -54,939.63 | - | - |
| (一)基本每股收益 | 0.13 | 0.34 | 0.23 | 0.21 |
| (二)稀释每股收益 | 0.13 | 0.34 | 0.23 | 0.21 |
| 九、综合收益总额 | 14,962,869.89 | 40,162,971.25 | 28,116,806.63 | 24,736,348.93 |
| 归属于母公司股东的综合收益总额 | 15,036,959.76 | 40,217,910.88 | 28,116,806.63 | 24,736,348.93 |
| 归属于少数股东的综合收益总额 | -74,089.87 | -54,939.63 | - | - |
| 公告日期 | 2025-04-21 | 2025-04-21 | 2024-10-26 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |